Where Will Immunitybio Inc (IBRX) Stock Go Next After It Is Lower By 12.20% in a Week?

Overall market sentiment has been down on Immunitybio Inc (IBRX) stock lately. IBRX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Immunitybio Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on IBRX!

See Full IBRX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With IBRX Stock Today?

Immunitybio Inc (IBRX) stock is trading at $3.31 as of 11:33 AM on Tuesday, Jan 23, a drop of -$0.34, or -9.32% from the previous closing price of $3.65. The stock has traded between $3.30 and $3.80 so far today. Volume today is low. So far 1,237,661 shares have traded compared to average volume of 4,420,003 shares. To see InvestorsObserver's Sentiment Score for Immunitybio Inc click here.

More About Immunitybio Inc

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Click Here to get the full Stock Report for Immunitybio Inc stock.